<DOC>
	<DOCNO>NCT00486499</DOCNO>
	<brief_summary>hypothesis : short half-life Pd-103 versus I-125 , increase rate tumor eradication . A total 660 patient AJC clinical stage T1c-T2a prostatic carcinoma ( Gleason grade 7 9 and/or PSA 10–20 ng/ml ) randomize implantation I-125 ( 144 Gy ) versus Pd-103 ( 124 Gy ) .</brief_summary>
	<brief_title>I-125 Versus Pd-103 Medium Risk Prostate Cancer</brief_title>
	<detailed_description>Objective : The objective study test hypothesis short half-life Pd-103 versus I-125 , increase rate tumor eradication . Research plan : A total 660 patient AJC clinical stage T1c-T2a prostatic carcinoma ( Gleason grade 7 9 and/or PSA 10–20 ng/ml ) randomize implantation I-125 ( 144 Gy ) versus Pd-103 ( 124 Gy ) . Methodology : Randomization accomplish method random permute block . Cancer status monitor yearly serial serum PSA . Treatment-related morbidity monitor personal interview , use standard American Urologic Association Radiation Therapy Oncology Group criteria 1 , 3 , 6 , 12 24 month . Primary endpoint : Time treatment failure . Patients serum PSA 0.5 ng/ml two year treatment consider residual recurrent cancer fail therapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>PSA 410 ng/ml Gleason score 5 6</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>radiation</keyword>
	<keyword>brachytherapy</keyword>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
</DOC>